AI医疗行业解决方案白皮书
The Underlying Drivers of Change in the 2.1 Industry
The Underlying Drivers of Change in the 2.1 Industry
The healthcare industry is facing unprecedented structural challenges:
Increased imbalance between supply and demand:
-The number of imaging doctors in China is only 0.17 per thousand, far below the level of developed countries.
-The training cycle of senior diagnostician is as long as 10-15 years, and the talent supply is far from keeping up with the growing health demand.
-High-quality medical resources are highly concentrated in the top three hospitals in big cities, and the problem of "difficult medical treatment and slow diagnosis" at the grassroots level is prominent.
Cost pressures continue to rise:
-Global health spending as a share of GDP continues to rise, and cost control has become the core of national policies.
-Traditional drug research and development "10 billion" model is not sustainable, the need for technological paradigm breakthrough
-High human costs for hospital operations, with doctors' paperwork accounting for 2-3 hours/hour of clinical time for medical services
The technical inflection point has arrived:
-Breakthroughs in large language models and generative AI have enabled AI to move from "perceptual intelligence" to "cognitive intelligence"
-Multi-modal fusion technology to break the data barriers between images, text, genes, physiological signals
-AI intelligence (AI Agent) evolves AI from "passive answer" to "active execution"
2.2 Paradigm Transition from "Tool Empowerment" to "Native Reconstruction"
From the perspective of industrial evolution, the development of AI medical care can be roughly divided into two stages:
Phase 1: Tool Empowerment Period (2014-2023)
At this stage, AI are mainly embedded in all aspects of medical services as auxiliary tools, such as image screening, online pre-consultation, medical record voice entry, etc. Its core value lies in improving local efficiency and reducing operating costs, but it is essentially an incremental optimization of existing medical processes and has not yet touched the core operating logic of medical services. AI products are mainly single-point function software, each system is independent of each other, and the phenomenon of data island is common.
Phase II: Native Reconstruction Period (2024-present)
With the breakthrough of large language model and multimodal technology, the positioning of AI begins to transition from "auxiliary tool" to "industry base. Its core features include:
-The medical large model has evolved from "general-purpose" to "disease-specific Junior College", and the accuracy and reliability of the model in specific clinical scenarios have been significantly improved.
-AI-assisted diagnosis has been incorporated into the national health insurance payment system, marking the formal change of AI health care from a "product" to a "commodity", establishing a sustainable business model.
-The role of hospitals has undergone a fundamental change-from AI "users" to "R & D participants". Some top hospitals have developed vertical medical models on the basis of general models, and independent R & D accounts for nearly 25%.
-38 top hospitals across the country have developed 55 vertical medical models for specific departments using the common large model base.
-The rise of AI intelligence (AI Agent) has led AI from "passive response" to "active execution", and the organization of medical services has begun to be redefined.
2.3 2026: A Critical Turning Point for AI Healthcare Commercialization
2026 is the turning point of AI medical care from "technical verification" to "commercial closed loop:
-Payment side to open:AI-assisted diagnosis into the health insurance category B, to solve the long-standing industry problem of "lack of charge code, lack of payer".
-Approval side accelerated: The first medical model entered the green channel of innovative medical devices, the industry from "filing" to "certification"
-Technical maturity: Large medical models have moved from "general but not refined" to "precise adaptation of clinical scenarios", with 288 models covering the entire department.
-Industry-side gathering: Capital from the "pursuit of the concept" to "focus on landing", the head of the enterprise began to run through the business model.
##3. global and Chinese AI healthcare market pattern
3.1 Global Market Panorama
| Indicator | Data |
|---|---|
| Global Market Size 2025 | About $37 billion |
| 2033 Forecast Size | Over $505 billion |
| Compound Annual Growth Rate (CAGR) | Approximately 39% |
| Vision 2034 | Over $1 trillion |
Source: The Global AI Healthcare Frontier Report, 2026
Regional Market Comparison:
| Region | Core Features | Iconic Policies |
|---|---|---|
| China | World's Largest AI Medical Single Market Expectations, Medicare Payments First Landing | AI Diagnostics Included in Medicare Category B, NMPA Accelerated Approval |
| US | AI start-up financing accounts for 54%-62% of the world. FDA PCCP framework allows algorithm to be continuously updated | FDA PCCP (Scheduled Change Control Plan) |
The AI Act sets strict compliance requirements for high-risk systems, and DiGA, Germany, is the first to establish a AI payment model. EU AI Act, German DiGA framework.
| INDIA | SAHI Strategy Promotes Rural AI Health Coverage with AI Diagnostic Software Listed as Class C Devices | SAHI National AI Health Strategy |
3.2 China Market Depth Analysis
Market Size Forecast:
| Year | Market Size | Drivers |
|---|---|---|
| 2025 | ~ 115.7 billion yuan | AI Image Approval Centralized Landing |
| 2026 | Over 40 billion yuan (medical AI industrialization caliber) | Medical insurance payment landed, commercial closed loop initially formed |
| 2028 | ~ 159.8 billion yuan | Large model intelligent body scale |
| 2030 | Over 200 billion yuan | Full Scene AI Medical Infrastructure Mature |
Data source: According to the comprehensive forecast of industry research institutions.
Key policy milestones:
| Time | Policy Event |
|---|---|
| April 2025 | National Health Commission Releases "Reference Guidelines for Artificial Intelligence Application Scenarios in Health Industry" |
April 2026 | AI Assisted Diagnosis Included in National Health Insurance Category B Catalogue, 12 Items, Reimbursement 70%-85% |
| May 2026 | The first three types of medical devices based on large model technology were approved (Deshi Bio).
| 2026 | National cumulative approved AI medical device three certificates nearly 90 |
| 2026 | National Health Commission and other five departments jointly issued "artificial intelligence + medical and health" implementation opinions |
Accelerated approval of AI three types of certificates:
Since the first AI Class III certificate was approved in 2020, the pace of approval has accelerated significantly:
-January 2026: It is estimated that the medical "finishing touch puncture surgical navigation equipment" has been approved-the first AI surgical navigation equipment in China
-February 2026: Wuhan Chu Spirit's "Electronic Endoscopic Image-Assisted Triage Software for Gastric Lesions" Approved-First Three Types of Gastric Cancer AI
-March 2026: Ambiping and Tencent Health "Cervical Cell Digital Pathology Image Auxiliary Diagnosis Software" Approved
-May 2026: United Shadow Intelligence "Chest CT Image Aided Diagnosis Software" Enters Green Channel of Innovative Medical Devices-First Large Model Multi-Disease AI Product
Technology Maturity Distribution of 3.3 Industry
According to the public industry research report (covering 600 industry practitioners), the popularity of AI medical scenarios is as follows:
| Scenarios | Adoption | Maturity |
|---|---|---|
| Medical Imaging and Diagnostics | 47% | Most mature and scaled |
| Clinical Decision Support | 43% | Rapid Growth |
| Disease diagnosis and risk prediction | 40% | Rapid growth |
| Administrative workflow optimization | 38% | Stable popularity |
| Virtual Health Assistant/Chatbot | 35% | Emerging Outbreak |
| AI Drug Research and Development | 57% (Pharmaceutical Enterprises) | Paradigm Change |
| Genomics Applications | 48% (Pharmaceutical Companies) | Accelerated Development |
Data source: According to the public industry research report.
Deep analysis of core application scenarios of 4. AI medical care
4.1 Scenario 1: Medical Imaging AI-From Single Disease Screening to Whole Disease Intelligent Diagnosis
4.1.1 Technology Maturity and Market Position
Medical imaging AI is the most mature and most permeable segment of AI medicine. As of 2026, there are 56 large model products focusing on medical imaging, covering the entire process of image acquisition, processing and diagnosis. Radiological imaging has the highest maturity, and ultrasound and pathology have become important breakthroughs.
DEEP DRIVING FORCE:
- The gap between supply and demand is the largest : the number of imaging examinations increases by 30% annually, and the growth rate of imaging doctors is less than 5%
-High degree of process standardization: DICOM/RIS workflow from image acquisition to report generation is naturally suitable for AI embedding
-Clear path to commercialization:AI products can be seamlessly embedded in PACS/RIS systems with minimal disruption to physician workflows
4.1.2 Technology Evolution: From Dedicated Models to Universal Pedestals
The application of image recognition AI in the medical field has experienced three technology generations:
Generation 1 (2018-2021): Single-task-specific model
-One model to solve a specific problem (lung nodule detection, fracture identification, etc.)
-Need a lot of labeled data, weak generalization ability
Second generation (2022-2024): Multi-task learning
-One model covers multiple lesions of the same organ
-Marking efficiency improved, but still not universal between organs
Third Generation (2025-2026): Universal Image Base Large Model
-De Shi biological iMedImage®Covering 19 imaging modalities, with over 90% coverage of clinical imaging scenes
-The joint shadow intelligent CT large model can identify nearly 100 kinds of abnormal lesions at a time, and has handled more than 2.5 million cases in total.
-"Universal base + lightweight fine-tuning" mode: only need hundreds of samples and several days of training to build high-precision disease models
4.1.3 Key Application Segmentation
Radiography:
| Product Direction | Representative Cases | Core Metrics |
|---|---|---|
| CT Screening of Pulmonary Nodules | United Shadow Intelligence and Informed Medical Treatment | Detection of 3mm Grade Tiny Nodules, Shortening Reading Time by 33% |
| CT Evaluation of Stroke | Viz. AI (US) | Detection of Large Vessel Occlusion, Reduction of D2T Time by 60 Minutes + |
| fracture X-ray detection | Aidoc, Gleamer | emergency missed diagnosis rate decreased, sensitivity 94% + |
| Cardiovascular CTA Evaluation | Neusoft Vasis Series | Coronary Stenosis Degree + Plaque Composition Analysis |
Ultrasound image:
-Pulse intelligence: the first three types of thyroid nodule ultrasound AI that can give benign and malignant suggestions in the country, with an accuracy of 96%
-Ultrasound AI moves from "assisted film viewing" to "assisted decision making"-providing a good or bad judgment, not just marking areas
Digital Pathology:
-Ruijin Ruizhi Pathological Model: Accurate Identification of Cancer Cells in Seconds, Accuracy Over 99%
-Ambiping + Tencent Health: Cervical Cytopathological AI Assisted Diagnosis Approved for Three Types of Certificates
-AI change the preliminary screening of pathological slices from daytime to automatic processing at night, and increase the daily processing capacity from more than 1000 sheets to unlimited
Endoscopic image:
-Wuhan Chu Spirit: China's First AI Three Types of Gastric Cancer
-AI real-time auxiliary identification of gastrointestinal early cancer lesions, guide biopsy site selection
4.1.4 Quantification of economic value
CT screening of pulmonary nodules as an example:
-The AI system completes the whole lung CT analysis in 40 seconds, and the efficiency is improved by more than 60%
-18 percent decrease in misdiagnosis of early stage lung cancer
-Pulmonary nodule follow-up management automation, follow-up compliance increased by 40%
Early-stage lung cancer was diagnosed 11 months earlier, and the 5-year survival rate jumped from 20% to 90%.
4.2 Scenario 2: Clinical Decision Support System (CDSS)-From Information Retrieval to Cognitive Reasoning
4.2.1 Limitations of Traditional CDSS and Breakthrough of New Generation
Traditional CDSS is based on a rule base and a knowledge graph and has three major limitations:
-Rules update lag, difficult to keep up with the trend of shortening half-life of medical knowledge
-Rigid scenario, unable to handle the complex situation of coexistence of multiple diseases
-High false alarm rate, "wolf" effect causes doctors to turn off reminders
The new generation of CDSS based on large models achieves qualitative change:
From" keyword matching "to" semantic understanding ": Understanding the context of the medical record, rather than a simple keyword trigger
From" single-point reminder "to" full-link reasoning ": Simulate the doctor's diagnosis and treatment thinking chain-"symptoms → checkup → diagnosis → treatment → follow-up"
From" black box conclusion "to" evidence-based explainable ": every step of reasoning is labeled with medical basis, such as "Zheng Yuanfang" AI the full score system of doctor qualification examination
4.2.2 Typical Products and Models
Mode 1: General AI Doctor
Artificial Intelligence Doctor of Zhongshan Third Hospital -- Reasoning Agent Based on Real Inpatient Cases and Complete Diagnosis and Treatment Path:
-Training data: 1.3 million real desensitization diagnosis and treatment data and 700000 clinical case reports
-Knowledge base: 2000 authoritative guidelines and expert consensus, 8 million OMAHA medical knowledge maps, and gold domain medical examination knowledge base
-Core competence: covering the whole chain of "symptoms → examination → diagnosis → treatment → follow-up"
-Key features: interpretable and traceable diagnostic recommendations and individualized treatment pathways
-Empowerment effect: the average treatment time has dropped significantly, and young doctors can quickly "master" the expert's ability.
Mode 2: Specialized Disease Junior College Vertical Intelligence
Wenzhou batch release of medical intelligence series:
| Agent | R & D Organization | Core Functions |
|---|---|---|
| EyeHealth Agent | Eye Optometry Hospital Affiliated to Wenyi University | Multimodal Primary Eye Health Screening and Management |
| Emergency AI Brain | Wenzhou People's Hospital | Emergency AI decision support for the whole process, greatly improving rescue efficiency |
| Facial Health Diagnostic Intelligence | Peace International Hospital | Integrating Million-Level Compliance Dataset, Diagnostic Aesthetic Assessment |
| AI operation code/medical record | Joint operation of multiple hospitals | Automatic generation of operation code and intelligent control of medical record quality |
Mode 3: Full process embedding in hospital
The practice of Changzhou First Hospital shows how AI reshape the whole process of a prefecture-level hospital:
- Outpatient Service : Intelligent Triage on AI Inquiry Screen → "Intelligent Record in Clinic" Automatically Generates Draft Medical Records, 3000 + Cases per Day
-Surgery: intra-operative dictation → 30 seconds to generate standardized surgical records → automatic synchronization of electronic medical records
- ward : wearable monitoring → central monitoring large screen → smart watch alarm linkage; Automatic monitoring of AI infusion
- Image : Automatic Identification of Pulmonary Nodules → Film Reading Time Shortened to Dozens of Seconds, Sensitivity 94% +
-Pathology: digital slice AI preliminary screening → remote consultation completed on the same day (originally at least 3 days)
- Air :5G-A Low-altitude Unmanned Aerial Vehicle Inspection → 26 Minutes on the Ground Shortened to 7 Minutes
4.2.3 Huawei Pangu Medical Large Model 3.0
As a dedicated medical large model for clinical scenarios, the Pangu 3.0 released in January 2026 demonstrates the potential of the medical large model in CDSS:
-Training data: 10 million + standardized clinical medical records, 5 million + medical images, 300000 + gene sequencing data
-Covered departments: Knowledge map of 23 clinical departments
-Performance improvement: The diagnostic accuracy rate is 18% higher than that of the previous generation, and the identification accuracy rate of early lung cancer/pancreatic cancer exceeds 92%
-Scenario design: automatic generation of multimodal image synchronous analysis report in radiology department (30 minutes → 3 minutes); Rapid identification of critical illness in emergency department (40% reduction in evaluation time)
4.3 Scenario 3: AI Drug Research and Development-Paradigm Revolution, "Billion in Ten Years" to "Ten Million in 18 Months"
4.3.1 Dilemma of Traditional Mode
-Average cost of R & D for a single new drug: $2.6 billion
-Average R & D cycle: 10-15 years
Preclinical stage success rate: less than 0.01 percent
-Final approval rate of candidate molecules entering phase I: about 10%
4.3.2 How AI Rewrite R & D Logic
AI completely changed the paradigm of drug development, from "trial and error screening" to "precision design":
Target Discovery and Validation:
-AI analysis of protein folding mechanisms (AlphaFold3 can predict the structure and interactions of all living molecules)
-New targets that take 5 years to discover with traditional methods, AI only 30 days
-Knowledge mapping of multi-omics data and systematic identification of disease-related target networks
Molecular Design and Optimization:
-Generic AI directly create new drug molecular skeletons
-Good pharmacokinetic properties with expected efficacy and low toxicity
-Preclinical development cycle compressed from 5 years to 8 months
Clinical Trial Optimization:
-AI patient screening: Accurate matching of subjects most likely to benefit, 3 times more efficient enrollment
-Virtual control group/digital twin: reduce the need for real control
-Adaptive test design: real-time adjustment of the test scheme
Drug repositioning:
-AI analysis of multi-target effects of existing drugs
-Finding new indications for older drugs at one-tenth the cost of new drug development
4.3.3 Breakthrough
- CAR-T cell therapy :AI optimized design, solid tumor control rate reached 52%, and treatment cost was reduced to less than 200000
-Rare disease drugs:AI acceleration has made it possible to develop rare diseases that were originally "untreatable".
-Antibiotic Discovery:MIT team uses AI to screen new antibiotics from 0.107 billion compounds to solve the drug resistance crisis
On behalf of the enterprise: yingsi intelligence (Insilico Medicine), Exscientia, Atomwise-a number of enterprises have AI designed candidate molecules into clinical trials.
4.4 Scenario 4: Smart Hospital Management-From "Human Management Hospital" to "Digital Intelligence Operation"
The application of AI in hospital management is moving from "auxiliary tool" to "operation center":
Intelligent scheduling and resource scheduling:
-AI optimize outpatient doctor scheduling based on historical attendance and weather/epidemic forecasts
-Operating room utilization increased by 15%-20%
-MRI/CT equipment appointment waiting time reduced by 30% on average
Medical Document Automation:
-Environmental Clinical Documentation Systems (Ambient Clinical AI) will generate approximately $0.6 billion in 2025, an increase of 2.4 times annually.
-Main manufacturers: Abridge, Suki, Nuance DAX Copilot, Epic built-in functions
-The doctor's paperwork time is reduced by 40%-60%, directly alleviating job burnout
Smart Supply Chain Management:
-AI forecast of medicine/consumables inventory to reduce waste
-Intelligent configuration of surgical instrument package to reduce sterilization cost
-Fine management of SPD consumables, saving 10%-15% of procurement costs
Medicare fee control and DRG/DIP management:
-AI assist the quality control of the first page of medical records to avoid DRG grouping deviation caused by coding errors
-Intelligent recommendation of clinical pathways to control costs while ensuring quality
-Medical insurance compliance review, automatic identification of unreasonable diagnosis and treatment behavior
4.5 Scenario 5: Active Health Management and Chronic Disease Prevention and Control
4.5.1 Transition from "Disease Treatment" to "Health Guard"
The core value of AI medical care is extending from the pre-diagnosis-in-diagnosis-after-diagnosis "to the more pre-positioned" health management:
Wearable + AI monitoring:
-Continuous blood glucose monitoring (CGM)+ AI warning: abnormal 72 hours in advance prediction
-ECG continuous monitoring + AI analysis: atrial fibrillation detection rate increased by 3 times
-Ambulatory monitoring of blood pressure + AI intervention recommendations: hypertension control rate increased from 30% to 65%
Chronic Disease Smart Housekeeper:
-AI customized personalized diet, exercise, medication regimen
-Integrated intervention based on genetic, lifestyle and environmental data
-Regular follow-up of AI health coaches (e. g. Huma, Woebot, Wysa virtual care intelligences)
Smart Care for the Elderly:
-AI fall detection + automatic call for help, the safety of the elderly living alone increased by 90%
-Smart Mattress Monitoring Heart Rate Breathing Off-Bed Status
-AI wheelchair automatic obstacle avoidance navigation
4.6 Scenario 6: Public Health and Epidemiological Surveillance
-AI semantic analysis of social media and search engine keywords to detect outbreak signals 7-14 days earlier than official reports
-Pathogen genome AI analysis, rapid identification of new variants
-Acceleration of vaccine and drug development AI and dramatic shortening of pandemic response cycles
-AI decision of medical resource allocation, dynamic allocation of ICU beds/ventilator/medical staff
4.7 Scenario 7: Primary Health Care AI Empowerment-Bridging the Gap between Urban and Rural Health Care
-AI portable diagnostic equipment to enable village doctors to have "tertiary hospital capacity"
-Primary general practitioners AI assist in decision-making, and the diagnostic accuracy rate has been improved to close to the top three level.
-Remote AI imaging diagnostic network, covering remote areas
-National Target: AI Assisted Diagnosis Sinks to County Medical Co-operation in 2027
##5. business landing mode inside and outside the hospital
5.1 Hospital Commercialization Path
From the current industrial practice, the commercialization of hospital AI has formed three main paths:
Path 1: Information System Integration Embedding
AI is embedded as a functional module of HIS/EMR/PACS system, and commercial income is realized through hospital information construction projects. The advantage of this path is that the deployment resistance is small, the contract volume is large, and the AI capacity naturally penetrates into the daily operation of the hospital with the system upgrade. However, its limitation is that the value of AI is difficult to quantify and price independently, and it is easy to be underestimated in the overall information project budget.
Path 2: Registration and Sales of Independent Medical Devices
Through the approval of NMPA three-type certificate, AI products enter the market as independent medical devices and can be charged according to equipment, annual authorization or inspection times. The significant advantage of this path is that the regulatory approval threshold forms a natural barrier to competition, and with the expansion of health insurance payment coverage, the payment channel has been clear. However, the challenge lies in the long approval cycle (2-4 years) and the need to invest a lot of clinical trial resources to prove the safety and effectiveness of the product in a real clinical environment.
Path 3: Hospital Operating Service Cost Item
As a means to improve the overall service quality of the hospital, the AI does not charge patients or medical insurance independently, but is included in the hospital operating service cost. This path is fast in deployment and high in usage, and is suitable for emerging AI products in the market incubation period. However, long-term sustainability faces some uncertainty as the profitability model relies on the hospital's annual budget arrangements.
5.2 Out-of-hospital Commercialization Path
ToG (government side):
-Regional imaging center/AI-assisted screening platform
-Public Health AI Surveillance System
-Primary Medical AI Empowerment Project
-Funding from government public health budgets
ToB (Enterprise):
-Drug R & D AI platform (most mature)
-Medical examination center AI auxiliary diagnosis
-Insurance AI underwriting and wind control.
-Medical device embedded AI
ToC (consumer side):
-AI health consultation/consultation
-Chronic Disease Management Subscription Service
-Personalized health program customization
-Diversified business models: subscription, pay-per-view, membership.
##6. typical solutions and benchmarking cases
6.1 Image AI Benchmark Case
Case 1: United Shadow Intelligence-CT Large Model Multi-Disease AI
-The first large model product to enter the green channel of innovative medical devices in China
-A single CT scan can identify nearly 100 abnormal lesions
-More than 30 hospitals have landed, handling more than 2.5 million cases in total.
-33% reduction in film reading time, 94% sensitivity for lung nodule detection +
Case 2: Dushi Biology-Large Model of Chromosome Karyotype Analysis
-The first three types of medical devices approved based on large model technology.
-Reporting period shortened from an average of 30 days to 4-7 days
-The sensitivity and specificity of chromosome number abnormality detection are both 100%
-30.6 market share of China's chromosome karyotype analysis in 2024 (industry first)
-The market is expected to increase to $2.04 billion by 2030, with a CAGR of up to 51.9 per cent
Case 3: Pulse Intelligence-Ultrasonic AI of Thyroid Nodules
-The first three types of ultrasound AI that can give benign and malignant suggestions in the country.
-Diagnostic accuracy 96%, highly consistent with histopathology
-Enabling primary ultrasound doctors to make a diagnosis close to the level of 3A
6.2 Clinical Decision Support Benchmark Case
Case 4: Artificial Intelligence Doctor of Zhongshan Third Hospital
Zhongshan Third Hospital Golden Domain Medical Unicom Digital Intelligence Medical Joint Building:
-The first set of clinical intelligences based on real inpatient cases and complete treatment paths for reasoning.
-Training data: 1.3 million real desensitization diagnosis and treatment data, 700000 clinical case reports
-Knowledge Base: 2000 Guidelines Consensus 8 million OMAHA Knowledge Map
-Core value: interpretable and traceable individualized diagnosis and treatment path, so that the hospital's characteristic diagnosis and treatment knowledge can be transformed into a "inheritable" system capability.
-The three parties jointly build the "Medical Data Intelligence Joint Laboratory" and promote the new paradigm of "wet and dry integration"
Case 5: Changzhou First Hospital-Full Process AI Remodeling of Prefecture-level Hospitals
-AI comprehensive coverage from outpatient inquiry to surgical records, from pathological diagnosis to cross-hospital examination
-Outpatient: 3000 cases of medical records per day AI assisted generation
-Surgery: intra-operative dictation → 30 seconds to generate surgical records
-Pathology: AI night automatic preliminary screening day 1000 slices
-Air: 5G-A UAV for inspection, 26 minutes → 7 minutes
-Remote: Xinjiang Nilke County Hospital completed remote consultation on the same day (originally at least 3 days)
Case 6: Wenzhou Medical Intelligence Series
-10 AI medical intelligences covering eye health, emergency, skin, medical beauty, surgical coding, etc.
-Relying on China (Wenzhou) Digital Angang to build a compliant medical data system
-253 medical institutions have been covered, and 10.05 billion pieces of diagnosis and treatment data have been collected.
-20 high-quality medical data sets officially on the shelves of the data trading center
6.3 AI Drug Development Benchmark Case
Case 7: Yingsi Intelligence (Insilico Medicine)
-AI platform Pharma.AI covers the whole process of target discovery, molecular generation and clinical trial prediction
-First fully AI designed anti-fibrosis drug INS018_055 into Phase II clinical
-From target discovery to clinical candidate molecules in only 18 months, cost about $2.6 million (traditional 4.5 years, tens of millions of dollars)
-There are already 20 AI-designed drug candidates in the pipeline
6.4 Smart Hospital Management Benchmark Case
Case 8: AI Operation Management of a Provincial 3A Hospital
-AI the quality control of the first page of medical records: the coding error rate decreased from 12% to less than 2%
-Intelligent scheduling in operating room: utilization rate increased from 65% to 82%
-Outpatient AI triage: Average waiting time reduced from 42 minutes to 18 minutes
-Annual operating cost savings of about 30 million yuan
##7. AI medical technology architecture and platform capability
7.1 Overall Technical Architecture of Medical AI
┌──────────────────────────────────────────────────────────────┐
│ 应用层（全场景智能） │
│ ┌──────────┐ ┌──────────┐ ┌──────────┐ ┌──────────────┐ │
│ │ 影像诊断 │ │ 临床决策 │ │ 药物研发 │ │ 健康管理/运营│ │
│ │ CT/MR/DR │ │ CDSS/病历│ │ 靶点/分子 │ │ 排班/供应链 │ │
│ └──────────┘ └──────────┘ └──────────┘ └──────────────┘ │
├──────────────────────────────────────────────────────────────┤
│ 模型层（医疗AI中台） │
│ ┌──────────┐ ┌──────────┐ ┌──────────┐ ┌──────────────┐ │
│ │ 影像基座 │ │ 文本大模型│ │ 多模态融合│ │ 科学计算AI │ │
│ │ 大模型 │ │ 专病模型 │ │ 模型 │ │ 蛋白/基因组 │ │
│ └──────────┘ └──────────┘ └──────────┘ └──────────────┘ │
├──────────────────────────────────────────────────────────────┤
│ 数据层（医疗数据中台） │
│ ┌──────────┐ ┌──────────┐ ┌──────────┐ ┌──────────────┐ │
│ │ PACS/DICOM│ │ EMR/EHR │ │ 基因/组学 │ │ 可穿戴/IoT │ │
│ └──────────┘ └──────────┘ └──────────┘ └──────────────┘ │
├──────────────────────────────────────────────────────────────┤
│ 基础设施层 │
│ GPU算力集群 · 私有云/混合云 · 边缘计算节点 │
└──────────────────────────────────────────────────────────────┘7.2 key technology enable
Multimodal Data Fusion:
-Break the data barriers between PACS images, EMR texts, LIS tests, and gene sequencing
-Build a "digital patient" holographic model to achieve full-dimensional diagnosis and treatment evaluation.
-Alibaba Cloud Multimodal Fusion System, Zhongshan Hospital, Fudan University: Integrate image text to test the genetic data of wearable devices
Knowledge enhancement and domain adaptation:
-RAG (Retrieval Enhanced Generation): Combines real-time medical knowledge base with LLM to reduce "AI hallucinations"
-Evidence-based reasoning engine: Each diagnostic decision is labeled with a source of medical evidence.
-Knowledge map of special diseases: standardized diagnosis of 23 departments-treatment path
Medical AI Intelligence (Medical AI Agent):
-Evolved from "passive answer" to "active execution"-automatic pre-consultation, automatic generation of medical records, automatic follow-up arrangements
-Multi-intelligent body collaboration: diagnostic intelligent body inspection intelligent body image intelligent body treatment intelligent body work together.
-Human-machine collaborative workflow: AI handle routine tasks, doctors focus on complex decision-making and humanistic care
Federal Learning and Privacy Computing:
-Multi-center joint modeling without discharge zone
-Solve the dilemma of "unusable and dare not use" medical data
-Achieve "data availability invisible" to meet HIPAA/PIPL compliance requirements
7.3 From Single Hospital Deployment to Regional Healthcare AI Cloud"
-Current stage: Privatization deployment of single hospital, data not discharged area
-Evolution direction: regional healthcare AI cloud platform, multi-agency joint modeling federal reasoning
-Core competencies: Unified data standards, Model Zoo, A/B testing framework, MLOps O & M
##8. implementation path and ROI analysis
8.1 four-phase implementation roadmap
阶段一 阶段二 阶段三 阶段四
单点突破 科室覆盖 全院智能 生态协同
(1-6个月) (6-18个月) (18-36个月) (36个月+)
┌────────┐ ┌────────┐ ┌────────┐ ┌────────┐
│ 影像AI │ → │ 多科室 │ → │ 全流程 │ → │ 区域 │
│ 试点 │ │ AI覆盖 │ │ 智能体 │ │ 协作网 │
└────────┘ └────────┘ └────────┘ └────────┘Phase 1: Single point breakthrough (1-6 months)
-Select 1-2 pilot high-value scenarios (it is recommended to start from image AI or environmental medical record documents)
-Evaluate clinical outcomes, workflow fit, and physician adoption rates
-Measure the return on investment
Phase II: Section coverage (6-18 months)
-Expand the AI to radiology, pathology, ultrasound and other departments
-Build a unified data annotation and model training platform
-Train AI application team in hospital
Stage 3: Hospital-wide Intelligence (18-36 months)
-Introduction of clinical decision support and AI intelligence.
-From a single-point model to a hospital-wide AI center.
-Realize the comprehensive intelligence of diagnosis, treatment, medical records and management
Phase 4: Ecological Synergy (36 months)
-Participate in the regional medical AI collaboration network
-External output AI capability and special disease model
-Forming a AI innovation ecology of "medical, teaching, research and production" linkage
8.2 ROI Analysis
- Image AI scene ROI model (taking a medium-sized hospital with 50000 CT examinations per year as an example): *
| Item | Amount |
|---|---|
| Input | |
| AI imaging system (3-year license) | 900000 yuan |
| Server/GPU hardware | 300000 yuan |
| Implementation and Training | 200000 Yuan |
| Three-year total investment | 1.4 million yuan * |
| Earnings | |
| Film Reading Efficiency Improvement (Release of 1-2 Doctors Production Energy) | Annual 1 million yuan |
| Reduce Misdiagnosis Compensation (30%) | Annual 300000 yuan |
| Increase in Screening Revenue (Increase in Efficiency) | Annual 600000 Yuan |
| Annual total income | about 1.9 million yuan * |
| Payback period | Approximately 9 months |
- AI medical record document scene ROI (taking a hospital with an average monthly outpatient volume of 30000 as an example): *
| Item | Amount |
|---|---|
| Annual cost of environmental clinical documentation system | 500000 yuan |
| Doctors can save paperwork time every day | 1.5-2 hours |
| Equivalent to release doctor capacity | About 15% |
| annualized labor cost savings (based on released capacity) | about 1.2 million yuan |
| Increase in physician satisfaction (reduce burnout) | Indirect value |
| Payback period | Approximately 5 months |
8.3 industry effect reference
Based on combined data from multiple authoritative sources:
| Scene | Effect metrics | Data |
|---|---|---|
| AI Lung Nodule Screening | Nodule Detection Sensitivity | 94% + |
| AI Medical Record Documents | Document Time Reduced | 40%-60% |
| AI Pathology Screening | Cancer Cell Identification Accuracy | 99% + |
| AI Drug Development | Shortened Preclinical Cycle | From 5 Years to 8 Months |
| AI emergency triage | Critical illness assessment time reduced | 40% |
| AI procedure record | Record generation time | 30 seconds |
| AI chromosome analysis | Shortened reporting period | From 30 days to 4-7 days |
##9. Challenges, Governance and Compliance
9.1 Data Challenges
Data silos and barriers:
-The data between hospitals is not connected, "every hospital is a data island"
-Inconsistent PACS/EMR/LIS/HIS system interfaces, low data standardization
-Solution: FHIR standard promotion, regional medical data center, federal learning
Data quality and labeling costs:
-The labeling of medical data requires professional doctors and is extremely expensive (200-500 yuan/image)
-Solution: Weakly supervised/semi-supervised learning, synthetic data enhancement, active learning strategies
Data privacy and security:
-Medical data is the most sensitive personal information, and the consequences of leakage are extremely serious.
-Compliance requirements: HIPAA (US), Personal Information Protection Act (China), GDPR (EU)
-Solution: Private deployment, differential privacy, federal learning, secure multi-party computation
9.2 Regulation and Access Challenges
AI Medical Device Approval:
-China NMPA three-class certificate approval cycle 2-4 years
-US FDA 510(k)/De Novo/PMA path
-EU CE MDR certification
-Key Difficulty: Prove the safety, efficacy and generalization ability of the AI in a real clinical setting
Algorithm continuous update vs regulatory lock-in:
-AI models require continuous optimization, but regulations traditionally require "changes to be re-approved"
-US FDA PCCP (Scheduled Change Control Plan) provides institutional innovation for this contradiction
-China is also exploring a similar dynamic regulatory framework
Responsibility for AI decision-making:
-When there is an error in the AI-assisted diagnosis, how is the attribution of responsibility divided?
-The current industry consensus: AI as an auxiliary tool, the final decision-making power to the doctor.
-As AI autonomy increases, accountability frameworks need to evolve accordingly
9.3 Ethics and the Challenge of Fairness
-Algorithm bias: Single source of training data (mostly tertiary hospitals in large cities), which may lead to reduced accuracy of AI in rural/ethnic minority populations
-Digital Divide: Large numbers of hospitals in wealthy areas are AI, and the gap may be further widened in poor areas.
-Doctor-patient relationship: Does AI intervention affect doctors' humanistic care and empathy
9.4 Clinical Adoption Challenge
-AI trust: Doctors are wary of "black box" AI decisions
-Workflow embedding: The AI cannot be an additional operation step and must be naturally integrated into the existing workflow
-Change Management: From department heads to frontline nurses, continuous training and communication are required for the entire chain of AI.
- Industry research shows :85% of clinicians require a decisive voice in AI deployment
##10. Future Outlook: Towards a New Era of Active Health
10.1 Trend One: From "Image Leading" to "Full Scene Intelligence"
According to the judgment of all parties in the industry, the future evolution direction of AI medical treatment has been clear: from the current "single point tool" mode based on image diagnosis, it is gradually moving towards the "all-scene intelligent body" mode with virtual health assistant as the entrance and precision medical treatment as the goal.
In 2026, Wenzhou released 10 medical intelligences in batch and the landing application of artificial intelligence doctors in Zhongshan Third Hospital, marking the industry from "AI-assisted diagnosis" to a new stage of "AI whole process management. Under this trend, AI is no longer just a diagnostic module embedded in a department system, but a health management center throughout the whole process before, during and after diagnosis-it can actively collect patient information, intelligently triage, assist in making diagnosis and treatment plans, automatically generate medical documents, arrange follow-up plans, and truly become a "digital member" of the medical team ".
10.2 Trend 2: The medical big model moves from "generalization" to "specialization"
-Covering all departments from 1 general large model → 22 special disease Junior College vertical models
-Hospitals have changed from AI "users" to "developers", with 38 top hospitals developing 55 vertical models.
-Disease-specific model evidence-based reasoning engine to reduce "AI hallucinations" to clinically acceptable levels
10.3 Trend 3: AI medical devices from "auxiliary screening" to "auxiliary treatment"
-In 2026, it is estimated that the "key point puncture surgery navigation equipment" for medical treatment will be approved, marking the leap from "diagnosis" to "treatment" in AI.
-AI surgical robots, AI radiotherapy plans, AI personalized medicine programs-the treatment end AI is in full bloom.
-In the next 3-5 years, "AI-assisted therapy" will replicate the growth curve of "AI-assisted diagnosis".
10.4 Trend 4: AI-driven "digital health twin"
-Full range of digital twins based on clinical data of environmental exposure to personal genomic lifestyle
-"Preview" the trajectory of disease occurrence and development in the virtual world
-Achieve real "preventive treatment"-precise intervention before the disease occurs
10.5 Trend 5: Global AI healthcare regulation moves from "fragmented" to "synergistic convergence"
-FDA PCCP Framework, EU AI Act, China NMPA Innovation Approval-Three Regulatory Systems Towards Dialogue and Mutual Recognition
-IMDRF (International Medical Device Regulators Forum) promotes the AI of international standards for medical devices
-Multinational AI medical product listing path gradually smooth.
10.6 Trend 6: Brain-Computer Interfaces and Neuroregulation
-Neuralink and other brain-computer interfaces into human clinical trials
-AI decoding of EEG signals to restore motor/language function for paralyzed patients
-Neuromodulation AI precisely stimulates Parkinson's/Epilepsy/Depression targets
##11 Conclusions and Recommendations
11.1 Core Conclusions
- AI medical treatment has entered the stage of large-scale landing of "certificate to get, money to earn" : medical insurance payment through, three types of certificate accelerated approval, the first large model equipment approved, commercial closed loop initially formed
- Medical imaging AI is the most mature entrance, but the full-scene AI agent is the final: From "AI reading" to "AI full management", the industry is undergoing a paradigm upgrade from a single point to a full link.
- Hospital changes from" AI user "to" AI developer ":38 top hospitals have developed 55 vertical models, showing that medical institutions are not only users of technology, but also sources of innovation
- Data and compliance are the biggest bottlenecks and the strongest moat: high-quality disease-specific datasets and compliance systems will be the core competitive barriers for AI healthcare companies
- China's AI medical market will exceed 200 billion yuan in 2030 and will become the world's largest single market : policy first, population base and graded diagnosis and treatment demand resonate
11.2 Recommendations for Healthcare Institutions
Strategic level:
-Set up a special budget for AI medical care (it is recommended to account for 15%-25% of the information budget)
-From the image AI, gradually extended to CDSS, AI intelligence.
-Actively participate in the co-construction of specific disease data sets and vertical models to precipitate differentiation capabilities.
Implementation level:
-Select AI products compatible with existing PACS/EMR systems to reduce integration resistance
-Establish AI clinical effect evaluation mechanism, with data-driven continuous optimization
-Pay attention to doctor training and change management, get the recognition of front-line clinical staff
11.3 Recommendations for AI manufacturers
-From the "single disease model" to the "universal base lightweight fine-tuning" platform route, reduce the marginal cost of research and development.
-Deep integration into the hospital workflow, to achieve "zero perception integration", reduce the doctor's additional operation steps
-Build evidence-based reasoning to make AI decisions explainable and traceable, and build trust in doctors
-Active layout of medical insurance payment and three types of certificate approval, which is a commercial "admission ticket"
-Focus on primary care and home health management market, which is the next flashpoint
11.4's advice to investors
-Focus on image AI enterprises that have been approved for three types of certificates and cover high-frequency scenes (pulmonary nodules, fundus, cardiovascular)
-Continued focus on the AI drug development track-the biggest beneficiary of paradigm change
-Layout of the "AI service" model (virtual care, chronic disease management, health coaching),ToC market space is huge.
-Healthcare AI smart body infrastructure providers (data center, MLOps, federal learning platform) deserve long-term attention.
References 1. NVIDIA, "State of AI in Healthcare and Life Sciences: 2026 Trends", 2026 2. The Global AI Healthcare Frontier: A Strategic Analysis for Executives and Investors, 2026 3. People's Daily Online, "Artificial Intelligence Doctors in Zhongshan Third Hospital Coming Out", 2026.01 4. Xinhua, "Wenzhou mass release of medical intelligence AI technology into the whole process of diagnosis and treatment", 2026.05 5. Lookout, "From the Clinic to the Air: How AI Reshaped a Municipal Hospital", 2026.01 6. desh biology, "the first large model three-class certificate landing", 2026.05-06 7. National Health Commission, "Reference Guidelines for Artificial Intelligence Application Scenarios in Health Industry", 2025 8. National Health Insurance Administration, "AI-assisted diagnosis included in the medical insurance category B catalog", 2026.04.